iPS Cells & Regenerative Medicine– category –
-
Genomic Engineering Strategies and Alternative Cell Types in Allogeneic T-Cell Immunotherapy Platforms Enable Scalable Cancer Treatment
Academic Publication Global Overview Allogeneic T-cell therapy is emerging as a highly promising strategy in cancer immunotherapy due to its scalability and 'off-the-shelf' availability, overcoming logistical and manufacturing constraint... -
Allogeneic CAR-T Cell Therapies Promise to Overcome Autologous Challenges and Expand Therapeutic Potential in Solid Tumors
PubMed (Review Article) Global Overview This review article details how allogeneic CAR-T cell therapies demonstrate clinical benefits in B-cell malignancies and offer the potential to overcome key limitations of autologous CAR-T, such as... -
UCLA Health Accelerates Cancer Therapy Screening with 3D Bioprinting and AI-Integrated Platform
UCLA Health Jonsson Comprehensive Cancer Center USA Overview UCLA Health Jonsson Comprehensive Cancer Center researchers have developed an innovative platform combining 3D bioprinting, advanced imaging, and AI to rapidly identify promisi... -
First Report of CRISPR-Derived Base Editing in Human Embryos Achieves Precise DNA Changes While Avoiding Large Chromosomal Aberrations
CMN Weekly (CRISPR Medicine News) Unknown Overview CRISPR-derived base editing has been successfully applied to human embryos for the first time, achieving precise DNA changes while circumventing the large chromosomal aberrations typical... -
Intellia Therapeutics’ In Vivo CRISPR Therapy Lonvo-z Achieves 87% Attack Rate Reduction in HAE Phase 3 Trial, Initiates Rolling BLA Filing with FDA
Intellectia.AI USA Overview Intellia Therapeutics' in vivo CRISPR therapy, lonvo-z, demonstrated an 87% reduction in hereditary angioedema (HAE) attack frequency in its Phase 3 HAELO trial. Following these breakthrough results, the compa... -
Streamlining PBMC Processing in Multi-Site Clinical Trials Bridges Translational Gap in Drug Discovery
REPROCELL Blog Japan Overview Efficient processing of peripheral blood mononuclear cells (PBMCs) in multi-site clinical trials is crucial for bridging the translational gap in drug discovery. This article identifies key challenges and pr... -
CRISPR Gene Editing Advances in 2026: Accumulation of Clinical Data and Evolving Regulatory Framework for Rare Diseases, Cancer, and Autoimmune Disorders
Industry report / Analysis USA Overview The CRISPR gene editing landscape in 2026 shows significant progress across rare diseases, hematologic and solid cancers, and autoimmune disorders. Clinical programs are generating crucial data, wh... -
Beam Therapeutics Receives U.S. FDA IND Clearance for BEAM-304, a Base Editing Therapy for Phenylketonuria (PKU)
Beam Therapeutics USA Overview Beam Therapeutics announced U.S. FDA Investigational New Drug (IND) clearance for BEAM-304, its investigational base editing therapy for Phenylketonuria (PKU). This milestone paves the way for human clinica... -
CRISPR Therapeutics Stock Volatility Driven by CASGEVY Commercialization and CTX112 Clinical Progress
Investing.com USA Overview CRISPR Therapeutics has experienced significant stock volatility due to market reactions to the commercialization of its approved CRISPR gene therapy, CASGEVY, and clinical developments for its off-the-shelf CA... -
iPS Cells & Regenerative Medicine Weekly Report May 20, 2026
▼ ▼ ▼ If you found the infographic compelling and want to read the full Weekly Report, click below to download the Strategy Report. ▼ ▼ ▼ 📄 iPS Cells & Regenerative Medicine Weekly Report — June 20, 2026 iPS_RegenerativeMedicine_WeeklyR...
